Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Micah Lance who wrote (57102)

4/5/2016 4:24:50 AM

From: Ditchdigger

Read Replies (2) | Respond to of 78656

Personally I think these sector rotation models are useful for identifying sector performance anomalies.
Might be getting sick of me pounding the healthcare sector table, but to me this is where an anomaly lies.
Consumer staples have been pushed to highs w/yields of 1, 2-3%, Utilities again have been pushed up, but are still yielding near 4%(I suspect they can hold these levels for awhile longer)....and wedged in the middle is healthcare, with dismal performance compared to the other 2. Imo this is a result of outside factors, election campaign rhetoric, Obama seeking an undeserved legacy, the senate etc.

I'd like to add another pharma stock, any suggestions out there? Looking at LLY from a technical standpoint.
Currently holding ABBV ,MRK
and VGHCX
VGHCX top 10:
Top 10 Holdings (41.18% of Total Assets)

CompanySymbol% AssetsYTD Return %

Allergan plc Ordinary Shares	AGN	6.56	N/A
Bristol-Myers Squibb Company Co	BMY	6.09	N/A
UnitedHealth Group Incorporated	UNH	5.28	N/A
Merck & Company, Inc. Common St	MRK	5.10	N/A
Eli Lilly and Company Common St	LLY	3.97	N/A
AstraZeneca PLC	AZNCF.L	3.84	N/A
Medtronic plc. Ordinary Shares	MDT	2.96	N/A
Mylan N.V.	MYL	2.51	N/A
McKesson Corporation Common Sto	MCK	2.50	N/A
Regeneron Pharmaceuticals, Inc.	REGN	2.37	N/